Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,210 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 1: Placebo Clear all
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

NCT04571424
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB133 (Dapirolizumab pegol), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

NCT04723394
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
24
States / cities
Jasper, Alabama • Tucson, Arizona • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis

NCT04066205
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
SLEEPSAMRT
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
8 Years to 13 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

NCT01194466
View directory record Official record
Conditions
Head Cancer, Neck Cancer, Pain
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Jennifer E. Lee
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 4, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Defining Neurobiological Links Between Substance Use and Mental Illness

NCT05538910
View directory record Official record
Conditions
Major Depressive Disorder, Substance Use Disorder, Normal Physiology
Interventions
Placebo Nicotine Patch, Nicotine Patch
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

NCT00775203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 4, 2026, 1:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Examine the Efficacy of a Supplement to Support Healthy Hair and Skin

NCT06579742
View directory record Official record
Conditions
Hair Thinning, Hair Loss
Interventions
Live Conscious Beyond Collagen, Placebo
Dietary Supplement
Lead sponsor
Scale Media Inc
Industry
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

NCT01059864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 4, 2026, 1:30 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Magnesium L-Threonate on Sleep, Recovery, and Athletic Performance in Collegiate Athletes

NCT07015047
View directory record Official record
Conditions
Recovery of Function (G11.427.698.620), Athletic Performance, Heart Rate Variability (HRV)
Interventions
Magnesium L-Threonate, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

NCT02597049
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Encino, California • Huntington Park, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 4, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

NCT00306150
View directory record Official record
Conditions
Blood Loss, Surgical, Postoperative Hemorrhage
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

NCT03349710
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Cetuximab, Cisplatin, Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

NCT06219915
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance

NCT07024940
View directory record Official record
Conditions
Coffee, Anthocyanins, Exercise Performance
Interventions
Ethiopian Coffee, Supplement, Water (Placebo)
Other · Dietary Supplement
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

NCT03255915
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC), Placebo
Drug · Other
Lead sponsor
Oak Crest Institute of Science
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication

NCT07806838
View directory record Official record
Conditions
Obesity & Overweight, Muscle Mass and Strength, Muscle Function
Interventions
Whey Protein Supplementation, Maltodextrin Placebo Capsules, Mixed Spice Capsules
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)

NCT05283525
View directory record Official record
Conditions
Body Weight Changes
Interventions
Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches, Oxygen Saturation, Total Blood Chemistry, Adverse Event Monitoring, Body Weight Monitoring, Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health
Dietary Supplement
Lead sponsor
Victory Nutrition International, Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Huntingdon Valley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

NCT02730455
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 4, 2026, 1:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

UB-312 in Patients With Synucleinopathies

NCT05634876
View directory record Official record
Conditions
Multiple System Atrophy, Parkinson Disease
Interventions
UB-312 Injection, Placebo Injection
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 4, 2026, 1:30 AM EDT
Completed Phase 3 Interventional

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

NCT00053976
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Daclizumab, methylprednisolone, Placebo
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
8
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 4, 2026, 1:30 AM EDT